Drug intelligence / Profile preview

VIS564

Development stage: Unknown
Lead developer: Visterra
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

VIS564 is a therapeutic candidate being developed by Visterra for the treatment of complement-mediated diseases. It is a monoclonal antibody designed to target and inhibit the C5a receptor 1 (C5aR1), a key component of the complement system's inflammatory cascade. By blocking the interaction between the anaphylatoxin C5a and its receptor C5aR1, VIS564 aims to suppress the recruitment and activation of inflammatory cells, thereby reducing tissue damage in various autoimmune and inflammatory conditions. The drug is currently in Phase 1 clinical development and was engineered using Visterra's proprietary Hierotope platform.

Targets

C5AR1 (Complement C5a receptor 1)

Beyond the preview

Go deeper on VIS564.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VIS564.

Explore the full profile